Tamsin Robb
Has grant
Research Associate
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
From molecules to medical imaging; a transdisciplinary approach to improving breast cancer prognostic tests for New Zealand women
Open Date: 2023-03-01
Close Date: 2024-09-01
Grant: Close
Charles Fleming Fund - Senior Scientist Award
Open Date: 2018-05-01
Close Date: 2019-05-01
Grant: Close
PathNote: a novel app to annotate valuable tissue bank samples
Open Date: 2018-04-01
Close Date: 2019-04-01
Grant: Close
Research support for doctoral scholarship: "Tumour heterogeneity: a patient-specific multi-layered investigation"
Open Date: 2018-03-01
Close Date: 2022-04-01
Grant: Close
"Tumour heterogeneity: a patient-specific multi-layered investigation"
Open Date: 2018-03-01
Close Date: 2022-04-01
Articles (6)
Year:
2025
Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombination (HR) repair pathways. Patients and Methods: The primary objective was to measure PARP inhibition, and the secondary objectives were to assess safety and feasibility. Participants received olaparib for 2 weeks before prostatectomy and were randomly assigned or not assigned (1:1) to degarelix. We analyzed diagnostic biopsy and radical prostatectomy samples for PARylated protein expression using IHC. Exploratory analyses included tumor gene sequencing, mutation analysis, and RNA sequencing (RNA-seq) using both bulk and single-cell RNA-seq performed on pretreatment and posttreatment tissues. Results: PARylated protein expression was significantly reduced in both cohorts, with no drug-related delays in radical prostatectomy. The gene set enrichment analysis identified distinct treatment response signatures related to olaparib in both cohorts and showed downregulation of androgen response genes after olaparib + degarelix treatment. Transcript profiling revealed an upregulation of the p53 hallmark, which was more pronounced with the combination treatment. Canonical cell-cycle progression hallmarks, including E2F targets and the G 2 –M checkpoint, were suppressed across all cases, correlating with a HR-deficient transcriptional signature. Single-nuclear RNA-seq indicated a greater increase in inflammatory response pathway activity within tumor epithelia after combination treatment. Conclusions: Transcriptomic analysis identified common hallmark alterations reflecting the combined impact of PARP inhibitor and androgen blockade on cell-cycle progression. We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.
Year:
2025
Year:
2024
Tumor evolution underlies many challenges facing precision oncology, and improving our understanding has the potential to improve clinical care. This study represents a rare opportunity to study tumor heterogeneity and evolution in a patient with an understudied cancer type. A patient with pulmonary atypical carcinoid, a neuroendocrine tumor, metastatic to 90 sites, requested and consented to donate tissues for research. 42 tumor samples collected at rapid autopsy from 14 anatomically distinct sites were analyzed through DNA whole-exome sequencing and RNA sequencing, and five analyzed through linked-read sequencing. Targeted DNA sequencing was completed on two clinical tissue biopsies and one blood plasma sample. Chromosomal alterations and gene variants accumulated over time, and specific chromosomal alterations preceded the single predicted gene driver variant (ARID1A). At the time of autopsy, all sites shared the gain of one copy of Chr 5, loss of one copy of Chr 6 and 21, chromothripsis of one copy of Chr 11, and 39 small variants. Two tumor clones (carrying additional variants) were detected at metastatic sites, and occasionally in different regions of the same organ (e.g., within the pancreas). Circulating tumor DNA (ctDNA) sequencing detected shared tumor variants in the blood plasma and captured marked genomic heterogeneity, including all metastatic clones but few private tumor variants. This study describes genomic tumor evolution and dissemination of a pulmonary atypical carcinoid donated by a single generous patient. It highlights the critical role of chromosomal alterations in tumor initiation and explores the potential of ctDNA analysis to represent genomically heterogeneous disease. Significance: DNA sequencing data from tumor samples and blood plasma from a single patient highlighted the critical early role of chromosomal alterations in atypical carcinoid tumor development. Common tumor variants were readily detected in the blood plasma, unlike emerging tumor variants, which has implications for using ctDNA to capture cancer evolution.
Year:
2023
Year:
2023
Year:
2023
Collaborators (10)
Vincent J. Gnanapragasam
Professor of Urology
University of Cambridge
Rexson Tse
Griffith University
Mark Linch
Associate Professor of Oncology
-
Cristin G. Print
University of Auckland
Polona Le Quesne Stabej
Senior Research Fellow
University of Auckland
Simon Pacey
-
Charlotta Windahl
Senior Lecturer
University of Auckland
Greg Shaw
Honorary Associate Professor
University College London
Grant McArthur
Lorenzo Galli Chair of Melanoma and Skin Cancers
University of Melbourne
ANNE WARREN
Associate Lecturer
University of Cambridge
Make your next move.
Prepare your application
Review drafts before you send them.